Biomaterial Database

Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur. 2002

Lin Zhang, and Daniel L Parsons, and Christine Navarre, and Uday B Kompella

Hoffman-La Roche, Nutley, NJ, USA.

The objective of this study was to develop sustained release Poloxamer 407 (P407) gel formulations of ceftiofur for treating foot infections in cattle. The formulations contained 25-35% (w/v) P407 alone or with polyvinyl pyrrolidone (PVP), carboxy methylcellulose (CMC), or hydroxylpropyl methylcellulose (HPMC) as an additive. The in-vitro release profiles of ceftiofur from the P407 formulations and the gel dissolution profiles were obtained simultaneously. Ceftiofur release followed zero order kinetics and correlated well with the weight percentage of P407 dissolved, indicating that the overall rate of release of ceftiofur is controlled by dissolution of the P407. An increase in P407 content from 25 to 35% resulted in a decrease in the rate of ceftiofur release. However, it appears that other factors may have also affected the drug release rate. Inclusion of PVP, CMC, and HPMC in the gel decreased the rate of release of ceftiofur to some extent. A decrease in the temperatures of the release medium decreased the release rate of ceftiofur, but not the rate of gel dissolution. The pH of the release medium showed a very slight effect on the release of ceftiofur and did not affect gel dissolution due to the non-ionic nature of P407.

UI	MeSH Term	Description	Entries
D002511	Cephalosporins	A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid.	Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D002626	Chemistry, Pharmaceutical	Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use.	Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D003692	Delayed-Action Preparations	Dosage forms of a drug that act over a period of time by controlled-release processes or technology.	Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004353	Drug Evaluation, Preclinical	Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.	Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005782	Gels	Colloids with a solid continuous phase and liquid as the dispersed phase; gels may be unstable when, due to temperature or other cause, the solid phase liquefies; the resulting colloid is called a sol.
D013678	Technology, Pharmaceutical	The application of scientific knowledge or technology to pharmacy and the pharmaceutical industry. It includes methods, techniques, and instrumentation in the manufacture, preparation, compounding, dispensing, packaging, and storing of drugs and other preparations used in diagnostic and determinative procedures, and in the treatment of patients.	Technology, Pharmacy,Pharmaceutic Technology,Pharmaceutical Technology,Pharmacy Technology,Technology, Pharmaceutic
D020442	Poloxamer	A nonionic polyoxyethylene-polyoxypropylene block co-polymer with the general formula HO(C2H4O)a(-C3H6O)b(C2H4O)aH. It is available in different grades which vary from liquids to solids. It is used as an emulsifying agent, solubilizing agent, surfactant, and wetting agent for antibiotics. Poloxamer is also used in ointment and suppository bases and as a tablet binder or coater. (Martindale The Extra Pharmacopoeia, 31st ed)	Pluronic,Poloxamers,Pluronic F-108,Pluronic F-127,Pluronic F-68,Pluronic F68,Pluronic L-101,Pluronic L-121,Pluronic L-81,Pluronics,Poloxalkol,Poloxamer 188,Poloxamer 213,Poloxamer 2930,Poloxamer 338,Poloxamer 407,188s, Poloxamer,213s, Poloxamer,2930s, Poloxamer,338s, Poloxamer,407s, Poloxamer,F68s, Pluronic,Pluronic F 108,Pluronic F 127,Pluronic F 68,Pluronic F108,Pluronic F127,Pluronic F68s,Pluronic L 101,Pluronic L 121,Pluronic L 81,Pluronic L101,Pluronic L121,Pluronic L81,Poloxalkols,Poloxamer 188s,Poloxamer 213s,Poloxamer 2930s,Poloxamer 338s,Poloxamer 407s

Related Publications

Lin Zhang, and Daniel L Parsons, and Christine Navarre, and Uday B Kompella

[In vitro and in vivo biodegradation of sustained-release vehicle poloxamer 407 in situ gel].

January 2008, Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery,

Lin Zhang, and Daniel L Parsons, and Christine Navarre, and Uday B Kompella

Evaluation of thermosensitive poloxamer 407 gel systems for the sustained release of estradiol in a fish model.

November 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,

Lin Zhang, and Daniel L Parsons, and Christine Navarre, and Uday B Kompella

Sustained release of lidocaine from Poloxamer 407 gels.

January 2005, International journal of pharmaceutics,

Lin Zhang, and Daniel L Parsons, and Christine Navarre, and Uday B Kompella

Sustained release of ketorolac tromethamine from poloxamer 407/cellulose nanofibrils graft nanocollagen based ophthalmic formulations.

November 2019, International journal of biological macromolecules,

Lin Zhang, and Daniel L Parsons, and Christine Navarre, and Uday B Kompella

Controlled release of morphine from a poloxamer 407 gel.

August 2013, International journal of pharmaceutics,

Lin Zhang, and Daniel L Parsons, and Christine Navarre, and Uday B Kompella

Poloxamer 407/188 Binary Thermosensitive Gel as a Moxidectin Delivery System: In Vitro Release and In Vivo Evaluation.

May 2022, Molecules (Basel, Switzerland),